NCT03337295

Brief Summary

The purpose of this study is to assess the correlation between the thickness of lipid layer and the meibomian gland dysfunction.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2016

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

October 14, 2016

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 8, 2017

Completed
23 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

November 8, 2017

Status Verified

November 1, 2017

Enrollment Period

1.8 years

First QC Date

October 14, 2016

Last Update Submit

November 6, 2017

Conditions

Meibomian Gland Dysfunction

Keywords

Meibomian Gland DysfunctionLipid Layer Thickness

Outcome Measures

Primary Outcomes (1)

  • Lipid Layer Thickness

    up to 2 years

Secondary Outcomes (1)

  • Atrophy of Meibomian Gland

    up to 2 years

Study Arms (2)

Low-MGD

High-MGD

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This study was consisted of patients who underwent the Meibomian Gland Dysfunction through the signs. The Office of Research Ethics,Eye Hospital of Wenzhou Medical University approved the study protocol, and all patients provided their informed consent.

You may qualify if:

  • Patients who underwent the Meibomian Gland Dysfunction through the signs.

You may not qualify if:

  • Eye surgery history

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wenzhou Medical University

Wenzhou, Zhejiang, 325027, China

Location

MeSH Terms

Conditions

Meibomian Gland Dysfunction

Condition Hierarchy (Ancestors)

Eyelid DiseasesEye Diseases

Study Officials

  • Yun-e Zhao, MD

    Wenzhou Medical University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Doctor

Study Record Dates

First Submitted

October 14, 2016

First Posted

November 8, 2017

Study Start

January 1, 2016

Primary Completion

November 1, 2017

Study Completion

December 1, 2017

Last Updated

November 8, 2017

Record last verified: 2017-11

Locations

CN(1)